Company intelligence / Profile preview
Keli Therapeutics
Lithuaniakeli.eu ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
The company’s lead program, KELI103—an allogeneic placental mesenchymal stem cell therapy—is in preclinical development for acute respiratory distress syndrome. The company reports strong scientific data from in vitro, ex vivo, and in vivo studies across several non-clinical models. Manufacturing processes are GMP-compatible with a focus on scalability and reproducibility.
No clinical results have been published as the programs remain preclinical.
- Therapeutic areas
- PulmonologyOther
- Modalities
- Allogeneic placental mesenchymal stem cellsExosomesAdherent cell therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
PELOBiotech GmbH distributes their products/cell lines internationally as part of a supplier network.
Beyond the preview
Go deeper on Keli Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Keli Therapeutics.